Analyzing Sagimet Biosciences (NASDAQ:SGMT) & Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Profitability

This table compares Lisata Therapeutics and Sagimet Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Risk & Volatility

Lisata Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.46, meaning that its share price is 246% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lisata Therapeutics and Sagimet Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$100,000.00	113.44	-$16.59 million	($1.64)	-0.64
Sagimet Biosciences	$2.00 million	307.97	-$51.04 million	($1.28)	-7.74

Lisata Therapeutics has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Lisata Therapeutics and Sagimet Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Sagimet Biosciences	2	1	9	0	2.58

Sagimet Biosciences has a consensus target price of $26.63, suggesting a potential upside of 168.79%. Given Sagimet Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Lisata Therapeutics.

Summary

Sagimet Biosciences beats Lisata Therapeutics on 11 of the 13 factors compared between the two stocks.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.